Table 2.
Analysis of the independent Validation Series A risk group predictions generated using the 160-gene prognostic signature
| Stage | No. Patients |
Kaplan Meier Analysis (160-gene signature assigned high/low risk categories) |
Cox Proportional Hazards Regression (160-gene signature assigned high/low risk categories) |
Receiver Operator Curve analysis (association with 5-year DSS) |
|||
|---|---|---|---|---|---|---|---|
| Univariate P-value | Hazard Ratio (95 % CI) | Multivariate P-value | Hazard Ratio (95 % CI) | P-value | AUC (95 % CI) | ||
| I & II |
264 |
<0.0001 |
2.26 (1.46 to 3.50) |
<0.0001 |
2.80 (1.83 to 4.28) |
0.0004 |
0.66 (0.59 to 0.71) |
| I |
201 |
0.0008 |
2.23 (1.30 to 3.84) |
<0.0001 |
3.00 (1.78 to 5.08) |
0.0002 |
0.68 (0.61 to 0.75) |
| IA |
93 |
0.18 |
1.76 (0.70 to 4.47) |
0.045 |
2.65 (1.029 to 6.83) |
0.019 |
0.69 (0.59 to 0.78) |
| IB |
97 |
0.0008 |
2.79 (1.38 to 5.64) |
<0.0001 |
5.44 (2.48 to 11.97) |
<0.0001 |
0.75 (0.65 to 0.83) |
| II |
63 |
0.048 |
2.00 (0.98 to 4.14) |
0.042 |
2.20 (1.034 to 4.69) |
0.56 |
0.56 (0.42 to 0.70) |
| IIA |
13 |
0.0097 |
5.57(1.59 to 19.59) |
0.048 |
28.21 (1.048 to 759.30) |
1.0 |
0.50 (0.17 to 0.83) |
| IIB | 44 | 0.42 | 1.47 (0.56 to 3.83) | 0.48 | 1.44 (0.52 to 4.027) | 0.57 | 0.57 (0.40 to 0.58) |
Cox Proportional Regression analysis included stage*, microarray type, gender, treatment and age. *where possible, eg.stage IA vs. IB were in the analysis of all Stage I patients.